Screener
Artiva Biotherapeutics, Inc. ARTV Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
FAQ
- What is Artiva Biotherapeutics, Inc.'s total liabilities?
- Artiva Biotherapeutics, Inc. (ARTV) reported total liabilities of $21.13M in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s total liabilities changed year-over-year?
- Artiva Biotherapeutics, Inc.'s total liabilities increased by 3.8% year-over-year, from $20.35M to $21.13M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s total liabilities?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s total liabilities has grown at a -35.7% compound annual growth rate (CAGR), from $50.72M to $20.97M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Artiva Biotherapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude